Ying Cheng
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
Papers in
- Oncology 200
- Lung Cancer Research Studies 77
- Cancer Immunotherapy and Biomarkers 57
- Colorectal Cancer Treatments and Studies 49
-
- Lung Cancer Treatments and Mutations 174
- Lung Cancer Diagnosis and Treatment 23
- Gastric Cancer Management and Outcomes 21
- Co-authors
- Yi-Long Lung Cancer Wu (47 shared papers)Tony S.K. Mok (19 shared papers)Kazuhiko Nakagawa (14 shared papers)Ki Hyeong Lee (8 shared papers)Xiangdong Zhou (8 shared papers)Jesus Corral (6 shared papers)R Cebolla Rosell (6 shared papers)Adam Płużański (6 shared papers)
- Journals
- Annals of Oncology (71 papers)Journal of Thoracic Oncology (38 papers)Lung Cancer (18 papers)Journal of Clinical Oncology (16 papers)The Lancet Respiratory Medicine (12 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Ying Cheng
437 papers receiving 32.4k citations
Ying Cheng's Hit Papers
Peers
Comparison fields: 5 of 176
- Oncology 16.6k
- Pulmonary and Respiratory Medicine 16.6k
- Cancer Research 3.2k
- Hepatology 644
- Immunology 1.6k
Countries citing papers authored by Ying Cheng
This map shows the geographic impact of Ying Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Cheng more than expected).
Fields of papers citing papers by Ying Cheng
This network shows the impact of papers produced by Ying Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Cheng. The network helps show where Ying Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Ying Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 462 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 4151 |
| 2 | Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 2909 |
| 3 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2691 |
| 4 | Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC Hit paper breakdown → | 2019 | 2202 |
| 5 | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 995 |
| 6 | Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction Hit paper breakdown → | 2016 | 810 |
| 7 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2015 | 647 |
| 8 | First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study Hit paper breakdown → | 2015 | 624 |
| 9 | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) Hit paper breakdown → | 2021 | 614 |
| 10 | Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma Hit paper breakdown → | 2021 | 558 |
| 11 | A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 Hit paper breakdown → | 2020 | 478 |
| 12 | Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC Hit paper breakdown → | 2023 | 452 |
| 13 | Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial Hit paper breakdown → | 2013 | 451 |
| 14 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Hit paper breakdown → | 2017 | 424 |
| 15 | Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations Hit paper breakdown → | 2018 | 376 |
| 16 | Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 368 |
| 17 | Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study Hit paper breakdown → | 2023 | 354 |
| 18 | Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial Hit paper breakdown → | 2021 | 318 |
| 19 | Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11) Hit paper breakdown → | 2020 | 306 |
| 20 | 2019 | 302 |
About Ying Cheng
Ying Cheng is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Surgery, having authored 462 papers that have together received 33.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (174 papers), Lung Cancer Research Studies (77 papers), Cancer Immunotherapy and Biomarkers (57 papers), Colorectal Cancer Treatments and Studies (49 papers), Lung Cancer Diagnosis and Treatment (23 papers), Gastric Cancer Management and Outcomes (21 papers), Neuroendocrine Tumor Research Advances (18 papers) and Cancer Genomics and Diagnostics (16 papers). The work is most often cited by research in Oncology (16.6k citations), Pulmonary and Respiratory Medicine (16.6k citations), Cancer Research (3.2k citations), Hepatology (644 citations) and Immunology (1.6k citations). Ying Cheng has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Yi-Long Lung Cancer Wu, Tony S.K. Mok, Kazuhiko Nakagawa, Ki Hyeong Lee, Xiangdong Zhou, Jesus Corral, R Cebolla Rosell, Adam Płużański, Seiji Niho and Maria Rita Migliorino. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, Journal of Clinical Oncology and The Lancet Respiratory Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.